Microbot Medical granted USPTO patent expanding LIBERTY system TAM to 6M+ US procedures

Microbot Medical Inc.

Patent covers modular robotic system with interchangeable tool-receiver units attachable to base.
IP portfolio now: 12 patents granted globally, 57 patent applications pending.
Enables future adaptation for wider endovascular procedures; US TAM could grow from 2.5M to 6M+ annual procedures.
Company continues commercial readiness plans for LIBERTY system while awaiting FDA 510(k) clearance.
CEO Harel Gadot: near-term focus remains on peripheral market and commercial readiness.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.